Among these, APR-246 is presently being investigated in phase I–III clinical trials in cancers that frequently show mutations in the TP53 gene, such as melanoma, esophageal cancer, high-grade serous ovarian cancer and myeloid malignancies [270,271,272]. Here, TP53 is linked to cancer.